Aspire Biopharma Holdings (ASBP) Prepaid Assets (2022 - 2026)
Aspire Biopharma Holdings (ASBP) posted quarterly Prepaid Assets of $890149.0 for Q1 2026, up 43.81% year-over-year from $618971.0 in Q1 2025, and up 1515.46% quarter-over-quarter from $55102.0 in Q4 2025.
Aspire Biopharma Holdings (ASBP) Prepaid Assets (2022 - 2026) Analysis & Trends
Aspire Biopharma Holdings (ASBP) has reported Prepaid Assets for 5 consecutive years, with $890149.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Prepaid Assets rose 43.81% year-over-year to $890149.0; the TTM figure through Mar 2026 stood at $890149.0 (up 43.81% YoY), while the FY2025 annual figure was $55102.0, down 61.83% from the prior year.
- Prepaid Assets improved to $890149.0 in Q1 2026 per ASBP's latest filing, from $55102.0 in the prior quarter.
- Across five years, Prepaid Assets topped out at $890149.0 in Q1 2026 and bottomed at $43052.0 in Q2 2024.
- Historically, Prepaid Assets has averaged $428390.5 across 5 years, with a median of $506123.0 in 2023.
- Annual changes were most pronounced in 2024 — Prepaid Assets plunged 89.77% — and 2025, when it soared 1719.17%.
- Aspire Biopharma Holdings' Prepaid Assets stood at $600493.0 in 2022, then plunged by 86.47% to $81223.0 in 2023, then jumped by 77.73% to $144356.0 in 2024, then tumbled by 61.83% to $55102.0 in 2025, then soared by 1515.46% to $890149.0 in 2026.
- Business Quant data shows ASBP's Prepaid Assets at $890149.0 in Q1 2026, $55102.0 in Q4 2025, and $419421.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Aspire Biopharma Holdings | 8.30 Mn | -3.86 Mn | -30,086.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 1.01 Mn |
| Mar 31, 2026 | 890,149.00 |
| Dec 31, 2025 | 55,102.00 |
| Sep 30, 2025 | 419,421.00 |
| Jun 30, 2025 | 783,189.00 |
| Mar 31, 2025 | 618,971.00 |
| Dec 31, 2024 | 144,356.00 |
| Jun 30, 2024 | 43,052.00 |
| Mar 31, 2024 | 65,577.00 |
| Dec 31, 2023 | 81,223.00 |
| Sep 30, 2023 | 253,082.00 |
| Jun 30, 2023 | 420,943.00 |
| Mar 31, 2023 | 591,303.00 |
| Dec 31, 2022 | 600,493.00 |
| Sep 30, 2022 | 613,357.00 |
| Jun 30, 2022 | 629,129.00 |
| Mar 31, 2022 | 644,901.00 |